MDL-28170 has no analgesic effect on CCI induced neuropathic pain in mice

Abstract

The calpain inhibitor MDL-28710 blocks the early local pro-inflammatory cytokine gene expression in mice after chronic constriction nerve injury (CCI). One-hundred-thirteen wild type mice of C57Bl/6J background received CCI of the right sciatic nerve. Mechanical paw withdrawal thresholds and thermal withdrawal latencies were investigated at baseline and at 1, 3, and 7 days after CCI. Three application regimens were used for MDL-28170: a) single injection 40 min before CCI; b) serial injections of MDL-28170 40 min before and up to day three after CCI; c) sustained application via intraperitoneal osmotic pumps. The control animals received the vehicle DMSO/PEG 400. The tolerable dose of MDL-28170 for mice was 30 mg/kg body weight, higher doses were lethal within the first hours after application. Mechanical withdrawal thresholds and thermal withdrawal latencies were reduced after CCI and did not normalize after single or serial injections, nor with application of MDL-28170 via osmotic pumps. Although the calpain inhibitor MDL-28170 inhibits the early local cytokine upregulation in the sciatic nerve after CCI, pain behavior is not altered. This finding implies that local cytokine upregulation after nerve injury alone is only one factor in the induction and maintenance of neuropathic pain.

Figure 1

Chemical structure of MDL 28,170 (N-benzyloxycarbonylvalylphenylalaninal).

Figure 2

Paw withdrawal thresholds to mechanical stimuli (a, c, e) and paw withdrawal latencies to thermal stimuli (b, d, f) in mice after chronic constriction injury (CCI) and different application regimes of MDL-28170.

Figure 3

Relative gene expression of TNF in mouse a) cortex, b) hippocampus, c) hypothalamus, d) thalamus, e) spinal cord 1 hour after CCI and after application of MDL-28170 or DMSO.